LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Chiusa

27.66 -1.85

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.28

Massimo

28.04

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+130.22% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	32M 1.5B
Apertura precedente	29.51
Chiusura precedente	27.66

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 giu 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 giu 2026, 15:41 UTC

I principali Market Mover

American Battery Shares Jump on Energy Department Victory

8 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 giu 2026, 23:37 UTC

Discorsi di Mercato

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 giu 2026, 23:25 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 21:57 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 giu 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

Salesforce Agrees to Buy m3ter

8 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

8 giu 2026, 19:22 UTC

Discorsi di Mercato

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 giu 2026, 19:01 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 giu 2026, 18:52 UTC

Discorsi di Mercato

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 giu 2026, 18:17 UTC

Discorsi di Mercato

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 giu 2026, 17:32 UTC

Discorsi di Mercato

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 giu 2026, 17:29 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

8 giu 2026, 16:55 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 giu 2026, 16:54 UTC

Acquisizioni, Fusioni, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 giu 2026, 16:40 UTC

Discorsi di Mercato

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 giu 2026, 16:31 UTC

Discorsi di Mercato

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 giu 2026, 16:27 UTC

Discorsi di Mercato

Mexican Inflation Seen Easing in May -- Market Talk

8 giu 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 giu 2026, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Orange Bought Stake From Lorca

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 giu 2026, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 giu 2026, 15:58 UTC

Discorsi di Mercato

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 giu 2026, 15:55 UTC

Discorsi di Mercato

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 giu 2026, 15:41 UTC

Discorsi di Mercato

Gold Falls Below 200-Day Moving Average -- Market Talk

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

130.22% in crescita

Previsioni per 12 mesi

Media 65.13 USD 130.22%

Alto 100 USD

Basso 33 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.